Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:AVTE NASDAQ:NLTX OTCMKTS:RZLTD OTCMKTS:WIZP On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAVTEAerovate Therapeutics$8.23+11.5%$8.67$56.35▼$105.00$238.55M0.9512,438 shs124,811 shsNLTXNeoleukin Therapeutics$19.99+1.2%$20.30$2.03▼$14.36$187.87M1.1150,104 shs134,942 shsRZLTDRezolute$7.00+0.6%$5.31$16.00▼$24.05$58.93M4.634,788 shs1.13 million shsWIZPMawson Infrastructure Group$0.42-1.7%$0.47$0.07▼$1.45$466.87M1.77141,517 shs433,057 shs The Best Nuclear Energy Stocks to BuyNuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAVTEAerovate Therapeutics+0.27%+9.01%-17.82%+4.98%-88.78%NLTXNeoleukin Therapeutics+0.20%-2.23%-11.59%+14.29%-44.89%RZLTDRezolute+6.26%+19.79%+29.61%+78.92%+60.37%WIZPMawson Infrastructure Group0.00%-4.13%-18.63%-23.32%-68.50%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationAVTEAerovate TherapeuticsN/AN/AN/AN/AN/AN/AN/AN/ANLTXNeoleukin TherapeuticsN/AN/AN/AN/AN/AN/AN/AN/ARZLTDRezoluteN/AN/AN/AN/AN/AN/AN/AN/AWIZPMawson Infrastructure GroupN/AN/AN/AN/AN/AN/AN/AN/ACompare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAVTEAerovate Therapeutics 0.00N/AN/AN/ANLTXNeoleukin Therapeutics 0.00N/AN/AN/ARZLTDRezolute 0.00N/AN/AN/AWIZPMawson Infrastructure Group 0.00N/AN/AN/ACompare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAVTEAerovate TherapeuticsN/AN/AN/AN/A$3.96 per shareN/ANLTXNeoleukin TherapeuticsN/AN/AN/AN/A$11.08 per shareN/ARZLTDRezoluteN/AN/AN/AN/A$1.24 per shareN/AWIZPMawson Infrastructure GroupN/AN/AN/AN/A$0.03 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAVTEAerovate Therapeutics-$75.52M-$1.70N/AN/AN/AN/A-90.19%-77.47%11/10/2025 (Estimated)NLTXNeoleukin Therapeutics-$57.56M-$3.11N/A∞N/AN/A-37.22%-30.91%N/ARZLTDRezolute-$20.33MN/A0.00∞N/AN/A-153.46%-111.71%N/AWIZPMawson Infrastructure Group-$3.45M-$0.33N/AN/AN/AN/AN/A-85.32%N/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthAVTEAerovate TherapeuticsN/AN/AN/AN/AN/ANLTXNeoleukin TherapeuticsN/AN/AN/AN/AN/ARZLTDRezoluteN/AN/AN/AN/AN/AWIZPMawson Infrastructure GroupN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAVTEAerovate TherapeuticsN/A8.788.78NLTXNeoleukin TherapeuticsN/A15.3315.33RZLTDRezoluteN/A3.263.26WIZPMawson Infrastructure GroupN/A1.131.13Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAVTEAerovate TherapeuticsN/ANLTXNeoleukin Therapeutics52.37%RZLTDRezoluteN/AWIZPMawson Infrastructure GroupN/AInsider OwnershipCompanyInsider OwnershipAVTEAerovate Therapeutics24.90%NLTXNeoleukin Therapeutics1.58%RZLTDRezolute4.60%WIZPMawson Infrastructure GroupN/ACompare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableAVTEAerovate Therapeutics2028.99 million21.69 millionOptionableNLTXNeoleukin Therapeutics909.40 million9.25 millionNo DataRZLTDRezolute238.42 millionN/ANot OptionableWIZPMawson Infrastructure Group2486.32 millionN/ANot OptionableRZLTD, AVTE, WIZP, and NLTX HeadlinesRecent News About These CompaniesMawson Infrastructure Group (OTCMKTS:WIZP) Stock Price Down 0% - Here's What HappenedAugust 1, 2025 | marketbeat.comH.C. Wainwright Sticks to Their Hold Rating for Mawson Infrastructure Group (MIGI)April 2, 2025 | markets.businessinsider.comMawson Infrastructure releases 2025 company presentationJanuary 28, 2025 | markets.businessinsider.comMawson Infrastructure names William Regan as CFOJanuary 17, 2025 | markets.businessinsider.comMawson Infrastructure reports December revenue $5.26M, up 7% month/monthJanuary 14, 2025 | markets.businessinsider.comMawson Infrastructure executes new customer agreementJanuary 7, 2025 | markets.businessinsider.comMawson Infrastructure Group Inc (MIGI) Stock Trading RecapDecember 10, 2024 | bovnews.comBCreditors file Chapter 11 involuntary petition against Mawson Infrastructure, latter vows to 'vigorously defend' itselfDecember 6, 2024 | bizjournals.comWhy Is Mawson Infrastructure Group Inc (MIGI) Stock Lagging Behind -56.76% from Its 50-Day SMA?December 6, 2024 | bovnews.comBMawson Infrastructure reports August revenue $4.44M; digital colocation business up 166% Y/YSeptember 16, 2024 | seekingalpha.comMawson Infrastructure Group Inc (MIGI) Stock: More Strategic Than Meets the EyeAugust 24, 2024 | bovnews.comBMawson Infra Gr (NASDAQ:MIGI) Stock, Short Interest ReportAugust 14, 2024 | benzinga.comMawson Infrastructure Group adds new customer at Midland bitcoin facilityDecember 20, 2023 | bizjournals.comMawson announces agreement for half of Midland bitcoin facility capacityOctober 19, 2023 | bizjournals.comMawson Infrastructure reports BTC production of 69 in July, down 3% M/MAugust 24, 2023 | seekingalpha.comH.C. Wainwright Sticks to Its Buy Rating for Mawson Infrastructure Group (MIGI)August 24, 2023 | markets.businessinsider.comMawson Infrastructure Group Inc. Invites Submission of Indication of Interest for its BTC Hosting and HPC Co-location ServicesJuly 25, 2023 | technews.tmcnet.comTMawson Infrastructure Group Inc. Announces Monthly Operational Update for June 2023July 19, 2023 | businesswire.comMawson Infrastructure Group Inc. Announces Monthly Operational Update for May 2023June 14, 2023 | technews.tmcnet.comTMawson Infrastructure Group names new president, CEOMay 22, 2023 | bizjournals.comWith Significant Increases In Megawatt Capacity And Bitcoin Production, Mawson Infrastructure Group (NASDAQ: MIGI) May Attract More Bitcoin Mining InvestorsApril 11, 2023 | msn.comMedia Sentiment Over TimeRZLTD, AVTE, WIZP, and NLTX Company DescriptionsAerovate Therapeutics NASDAQ:AVTE$8.23 +0.85 (+11.52%) As of 08/22/2025Aerovate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops drugs that enhance the lives of patients with rare cardiopulmonary diseases in the United States. It focuses on advancing AV-101, a dry powder inhaled formulation of imatinib for the treatment of pulmonary arterial hypertension, which is in Phase 2b/Phase 3 trial. The company was incorporated in 2018 and is headquartered in Waltham, Massachusetts.Neoleukin Therapeutics NASDAQ:NLTX$19.99 +0.24 (+1.22%) As of 08/22/2025Neoleukin Therapeutics, Inc., a biopharmaceutical company, develops immunotherapies for cancer, inflammation, and autoimmunity disorders using protein design technology. The company's lead product candidate is NL-201, a de novo protein designed to mimic the therapeutic activity of the cytokines interleukin (IL)-2/IL-15 for the treatment of various types of cancer, including renal cell carcinoma and melanoma. The company was formerly known as Aquinox Pharmaceuticals, Inc. and changed its name to Neoleukin Therapeutics, Inc. in August 2019. Neoleukin Therapeutics, Inc. was founded in 2003 and is headquartered in Seattle, Washington.Rezolute OTCMKTS:RZLTD$7.00 +0.04 (+0.57%) As of 08/22/2025Rezolute, Inc., a clinical stage biopharmaceutical company, develops therapies for rare and metabolic diseases in the United States. The company's lead product candidate is RZ358, a human monoclonal antibody that is in Phase 2b clinical trial for the treatment of congenital hyperinsulinism, an ultra-rare pediatric genetic disorder. It also develops RZ402, a small molecule plasma kallikrein inhibitor, which is in preclinical stage for the treatment of diabetic macular edema. The company was formerly known as AntriaBio, Inc. and changed its name to Rezolute, Inc. in December 2017. Rezolute, Inc. was founded in 2010 and is headquartered in Redwood City, California.Mawson Infrastructure Group OTCMKTS:WIZP$0.42 -0.01 (-1.65%) As of 08/22/2025Mawson Infrastructure Group, Inc. engages in the provision of digital asset infrastructure services. The company is headquartered in North Sydney, Australia. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Workday: Institutions Are Buying This Stock, Shouldn’t You? Alphabet’s Breakout Potential: From Laggard to AI Leader After Earnings Miss, Walmart Is Still a Top Consumer Staples Play Should You Join Buffett and Invest in Constellation Brands? Can Identity Security Fuel CrowdStrike’s Next Growth Phase? 3 Robotics Stocks at the Heart of the Robotics Revolution Analog Devices and an AI-Driven Semiconductor Supercycle Shopify’s Risk-Reward Profile Is Suddenly Red Hot Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access